GUCY1B1
ENSG00000061918
Target class
Enzyme
Chromosome
4
Approved drugs
8
Clinical candidates (approved and in development)
14
- Approved drugs
- 8
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- No
- Target name
- GUCY1B1
- Gene name
- Guanylate cyclase 1 soluble subunit beta 1
- Gene symbol
- GUCY1B1
- Protein name
- Guanylate cyclase soluble subunit beta-1 (GCS-beta-1) (EC 4.6.1.2) (Guanylate cyclase soluble subunit beta-3) (GCS-beta-3) (Soluble guanylate cyclase small subunit)
- GC-SB3
- GC-S-beta-1
- GUC1B3
- GUCY1B3
- Gene biotype
- Protein coding
- Gene family
- Soluble guanylate cyclases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 68.94
- Tissue specificity (Gini)
- 0.413
- Tissue specificity (tau)
- 0.737
- KEGG gene identifiers
- hsa:2983
- Protein interaction confidence
- 0.838655
- Protein interaction partners
- 29
- R-HSA-392154
- R-HSA-445355
- End position
- 155807811
- Start position
- 155758988
- Chromosome
- 4
- Strand
- Forward
- Cytoplasm .
- Cytosol
- Tissue specificity (tau)
- 0.736531
- Expression inequality (Gini)
- 0.412649
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 68.94
- Brain - Nucleus accumbens (basal ganglia)
- 53.43
- Colon - Sigmoid
- 47.53
- Artery - Tibial
- 43.28
- Brain - Anterior cingulate cortex (BA24)
- 39.07
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)68.94
- Brain - Nucleus accumbens (basal ganglia)53.43
- Colon - Sigmoid47.53
- Artery - Tibial43.28
- Brain - Anterior cingulate cortex (BA24)39.07
- Esophagus - Gastroesophageal Junction37.77
- Brain - Hypothalamus37.17
- Artery - Coronary36.63
- Brain - Cerebellar Hemisphere34.72
- Brain - Cortex34.05
- Brain - Caudate (basal ganglia)32.43
- Esophagus - Muscularis31.11
- Lung28.64
- Uterus28.34
- Cervix - Ectocervix26.6
- Brain - Cerebellum25.62
- Artery - Aorta24.99
- Brain - Putamen (basal ganglia)23.13
- Brain - Amygdala21.51
- Adipose - Subcutaneous20.91
- Cervix - Endocervix20.86
- Adipose - Visceral (Omentum)18.05
- Nerve - Tibial17.39
- Brain - Hippocampus17.15
- Colon - Transverse16.95
And 29 more, listed on the interactive page.
- GO:0006182
- GO:0038060
- GO:0005829
- GO:0008074
- GO:0004383
- GO:0005515
Related records
Trials (610)
- : Vascular Function in Health and Disease
- "Lignocaine vs GTN Ointment for Postoperative Pain After Hemorrhoidectomy")
- 1H Magnetic Resonance Spectroscopy in Migraine Patients
- 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
- A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
- A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis
- A Cohort Prospective Study of Predictors Influencing the Quality of Visualization of the Operating Field During Orthognathic Surgery
- A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control
- A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers
- A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis
- A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
- A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
- A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
- A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
- A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
- A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
- A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately
Drugs (16)
- Ataciguat Soluble guanylate cyclase activator
- Cinaciguat Soluble guanylate cyclase activator
- Isosorbide dinitrate Soluble guanylate cyclase activator
- Isosorbide mononitrate Soluble guanylate cyclase activator
- Methylene blue anhydrous Soluble guanylate cyclase inhibitor
- Methylene blue cation Soluble guanylate cyclase inhibitor
- Nitric oxide Soluble guanylate cyclase activator
- Nitroglycerin Soluble guanylate cyclase activator
- Nitroprusside Soluble guanylate cyclase activator
- Olinciguat Soluble guanylate cyclase positive allosteric modulator
- Pentaerythritol tetranitrate Soluble guanylate cyclase activator
- Praliciguat Soluble guanylate cyclase activator
- Riociguat Soluble guanylate cyclase positive allosteric modulator
- Runcaciguat Soluble guanylate cyclase activator
- Sodium nitroprusside Soluble guanylate cyclase activator
- Vericiguat Soluble guanylate cyclase activator